Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2010

View Archived Issues

A potential covalent HIV vaccine neutralizes diverse HIV strains

LLS and Shape Pharma join to develop SHP-141 in cutaneous T-cell lymphoma

SLC22A4, SLC22A5 and KIF3A SNPs linked to tuberculosis in Thai population

Trimetazidine add-on regimen is safe and effective in acute myocardial infarction

DiaMedica initiates autoimmune program with DM-99

Covidien acquires Somanetics

Isis Pharma achieves milestone in collaboration with GSK

Marina Biotech acquires Novosom's Smarticles delivery system

Pharmasset begins phase Ib PSI-938 trial in chronic hepatitis C

Addex Pharmaceuticals presents new mGlu4 receptor modulators

Bionovo moves Menerba to phase III testing in Europe

GlaxoSmithKline discloses novel CCR2 receptor antagonists

New antineoplastic agents identified by U.S. and Chinese scientists

Resverlogix claims new regulators of ApoA-I expression

Intercept and NIDDK join to develop obeticholic acid in NASH

New DPP-4 inhibitors described by Indian researchers

Optimer submits fidaxomicin MAA to EMA for CDI

HemaQuest raises extra funds to advance HQK-1001 and HQK-1004

Anthera begins phase IIb PEARL-SC trial of A-623 in SLE

Liposomal Grb-2 enters phase I trial in AML, CML, ALL and MDS

Daiichi Sankyo and Sanofi Pasteur end shareholder agreement for SPDS Vaccine

COMP recommends orphan drug status for XOMA-052 in Behcet's disease

GSK licenses new antibiotic for Gram-negative infections from Anacor

Methyl jasmonate is cytotoxic in cervical cancer cells irrespective of HPV status

Scientists identify DB-766 as new candidate therapeutic for Chagas' disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...